

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CANbridge Pharmaceuticals Inc.

北海康成製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1228)

CHANGE OF PROCESS AGENT

The board of directors (the “**Board**”) of CANbridge Pharmaceuticals Inc. (the “**Company**”) announces that with effect from 9 May 2023, Mr. Wai Chiu Wong was appointed as the authorized representative of the Company for accepting service of process and notices on behalf of the Company in Hong Kong (the “**Process Agent**”) as required under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) in place of Ms. Shuk Yi Betty So. Ms. Shuk Yi Betty So, who was appointed as the Process Agent on 18 May 2022, no longer acts as the Process Agent with effect from 9 May 2023.

By order of the Board
CANbridge Pharmaceuticals Inc.
Dr. James Qun Xue
Chairman

Hong Kong, 9 May 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. James Qun Xue as executive director; Dr. Kan Chen, Dr. Derek Paul Di Rocco and Mr. Edward Hu as non-executive directors; and Mr. James Arthur Geraghty, Dr. Richard James Gregory, Mr. Peng Kuan Chan and Dr. Lan Hu as independent non-executive directors.